Cantor Fitzgerald assumed coverage of Compass Pathways (CMPS) with an Overweight rating and $12 price target This is an important year for the psychedelic space in general with multiple randomized clinical trial data readouts, the analyst tells investors in a research note. The firm thinks there is potentially more upside to shares than options imply.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPS:
- Positive Outlook for COMPASS Pathways Amid Promising Clinical Developments and Strong Financial Position
- Positive Outlook for COMPASS Pathways: Buy Rating Backed by Promising Developments in Mental Health Treatments and Strong Financial Position
- Buy Rating Reiterated for COMPASS Pathways: Promising Phase 3 Trials and Strong Financial Position Highlighted
- Compass Pathways Reports Improved Quarterly Results
- Compass Pathways’ Earnings Call Highlights Progress and Challenges